Nestle Invests $200 Mln More in Aimmune After Peanut Allergy Drug Approval Nestle Invests $200 Mln More in Aimmune After Peanut Allergy Drug Approval

Aimmune Therapeutics Inc said on Wednesday the health science arm of Nestle SA will invest an additional $200 million in the drugmaker, bringing the Swiss company ' s total investment to $473 million.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news